
Clayton, Dubilier & Rice entities invested over $35.2 million in Resideo Technologies (REZI) shares between August 8-12, 2025, accumulating a significant stake as the stock approached its 52-week high. This substantial institutional buying coincides with Resideo's strong Q2 2025 financial performance, which saw the company beat EPS and revenue forecasts with $0.66 EPS and $1.94 billion revenue, alongside robust organic growth and nine consecutive quarters of gross margin expansion. Further reinforcing positive sentiment, Morgan Stanley upgraded REZI to Overweight, raising its price target to $35.00 from $24.00, indicating a potential 27% upside and signaling strong positive momentum for the company.
Resideo Technologies (REZI) is demonstrating significant positive momentum, driven by a confluence of substantial institutional buying, strong fundamental performance, and a bullish analyst revision. Entities linked to Clayton, Dubilier & Rice acquired over $35.2 million in REZI shares between August 8 and August 12, 2025, at prices ranging up to $31.49, which is notably close to the stock's 52-week high of $31.59. This buying at peak levels signals strong investor conviction, which is substantiated by the company's second-quarter 2025 financial results. Resideo surpassed forecasts with a revenue of $1.94 billion and an EPS of $0.66, representing a 22.22% earnings surprise. This performance was highlighted by the strongest organic revenue growth in 15 quarters and the ninth consecutive quarter of gross margin expansion in its Products & Solutions segment. The positive outlook is further validated by Morgan Stanley's upgrade to 'Overweight' and a price target increase to $35.00 from $24.00, implying a potential 27% upside and reinforcing the positive market sentiment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment